CS
PLRX icon

Candriam SCA’s Pliant Therapeutics PLRX Stock Holding History

Candriam SCA’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-900,104
Closed -$11.9M – 705
2024
Q4 		$11.9M Buy
900,104
+66,888
+8% +$913K 0.07% 241
2024
Q3 		$9.34M Hold
833,216
– – 0.05% 279
2024
Q2 		$8.96M Buy
833,216
+285,216
+52% +$3.68M 0.05% 270
2024
Q1 		$8.17M Buy
548,000
+95,000
+21% +$1.57M 0.05% 277
2023
Q4 		$8.2M Buy
453,000
+138,000
+44% +$2.1M 0.06% 279
2023
Q3 		$5.46M Buy
315,000
+50,000
+19% +$867K 0.04% 299
2023
Q2 		$4.8M Buy
265,000
+25,000
+10% +$592K 0.03% 343
2023
Q1 		$5.88M Buy
+240,000
New +$6.83M 0.04% 332

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Candriam SCA's PLRX Position: Q1 2025 in Review

Candriam SCA sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 900,104 shares — an estimated $11.9M sold.

Candriam SCA first reported a position in PLRX in Q1 2023 and held it in 8 quarters. The position peaked at $11.9M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

  • Candriam SCA reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Candriam SCA sold 900,104 Pliant Therapeutics shares in Q1 2025, an estimated $11.9M.
  • Candriam SCA first reported a position in Pliant Therapeutics in Q1 2023 and held it in 8 quarters.
  • Candriam SCA's Pliant Therapeutics position peaked at $11.9M in Q4 2024.
  • 140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Candriam SCA's 13F filing for Q1 2025, filed 14 May 2025.